LCTX

Business Context and Reporting Period

Company: BioTime, Inc. (Note: Metadata referenced Lineage Cell Therapeutics, but filing text identifies BioTime, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2008
Business Overview: BioTime is a biomedical organization engaged in the research and development of synthetic plasma expanders (Hextend, PentaLyte) and organ preservation solutions. In October 2007, the company entered the regenerative medicine field via a new subsidiary, Embryome Sciences, Inc., focusing on human embryonic stem cell products.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 55% to $381,018, driven primarily by a 55% increase in royalty revenue from product sales ($308,900 vs. $199,264). This reflects increased sales of Hextend to hospitals and the U.S. Armed Forces.
• Expense Increases: Total expenses rose to $783,090 from $761,330. General and administrative expenses increased due to higher stock-based compensation ($33,328 increase), legal fees, and travel expenses. Research and development expenses remained relatively flat, with increases in salaries and lab supplies offset by a decrease in outside research expenditures.
• Debt Expansion: Borrowings under lines of credit increased significantly. The company drew an additional $575,000 during the quarter, bringing total lines of credit payable to $1,307,328 (up from $716,537 at the end of 2007).
• Cash Position: Despite a net loss, cash on hand increased from $9,501 to $307,471, primarily due to net cash provided by financing activities ($569,608) from new borrowings.

Outlook, Risks, and Management Commentary

• Liquidity and Going Concern: The filing explicitly states that the financial statements are prepared assuming the company will continue as a going concern. BioTime has negative working capital of $1.66 million and an accumulated deficit of $44.3 million. Continued operations depend on raising additional capital, obtaining financing, or generating revenue.
• Financing Strategy: Management has instituted a cost-cutting plan. The company recently amended its revolving line of credit to increase the limit to $2.5 million and extend the maturity date to November 15, 2008. Lenders have the right to exchange notes for common stock at $1.00 per share.
• Strategic Shift: The company is pivoting toward regenerative medicine. A letter of intent was signed with International Stem Cell Corporation/Lifeline Cell Technology to jointly produce stem cell research products. BioTime paid $250,000 in April 2008 to initiate this collaboration.
• Revenue Recognition Timing: Royalties are recognized in the quarter the report is received, not when sales occur. Royalties of $341,153 received in April 2008 (based on Q1 sales) will be recognized in Q2 2008.
• Risks: Key risks include the uncertainty of clinical trial results, regulatory approvals (FDA), competition, and the ability to secure additional financing. The company has curtailed product development due to limited funds.

Investor Verification Checklist

• Cash Runway: Verify if the $307,471 cash balance and $2.5M credit line are sufficient to fund operations until the next financing event or revenue milestone.
• Debt Covenants: Review the specific triggers in the Credit Agreement that could force immediate repayment (e.g., raising $4M in equity or license fees).
• Stem Cell Collaboration: Confirm the status of the definitive agreement with Lifeline Cell Technology, as the $250,000 payment is refundable if the deal fails.
• Royalty Volatility: Assess the predictability of Hextend sales, particularly regarding large, intermittent orders from the U.S. Armed Forces.
• Dilution Risk: Monitor the issuance of shares to lenders (500,000 shares issuable as of March 31, 2008) and the Greenbelt financial advisory agreement (300,000 shares to be issued).